Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Sites / The Ohio State University Medical Center / Croce, Carlo

Croce, Carlo (M.D.)

PI, The Ohio State University Medical Center, 614-292-4930

Contact Information

Email: mailto:carlo.croce@osumc.edu
Fax:
EDRN Associate Member

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2) 0 0

Closed Protocols

No closed protocols.

Publications

Publication Name PubMed ID Journal
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. 22753494 Proc. Natl. Acad. Sci. U.S.A.
Clinical applications for microRNAs in cancer. 23212103 Clin. Pharmacol. Ther.
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. 23610125 J. Exp. Med.
miRNA profiling of cancer. 23465882 Curr. Opin. Genet. Dev.
A new role for microRNAs, as ligands of Toll-like receptors. 23296026 RNA Biol
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. 23505378 PLoS Genet.
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. 23405235 PLoS ONE
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. 23409773 Mol. Cancer
Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. 23589849 Proc. Natl. Acad. Sci. U.S.A.
MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. 23550646 Immunol. Rev.
miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. 19498445 Cell Death Differ.
miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. 19730444 Cell Death Differ.
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. 20332227 Cancer Res.
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. 21518799 J. Exp. Med.
Codeine-induced pulmonary oedema (an unusual cause of dyspnoea). 22315434 QJM
LINCing chromatin remodeling to metastasis. 20829831 Nat. Biotechnol.
Identification of microRNA activity by Targets' Reverse EXpression. 19897564 Bioinformatics
MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. 21057537 Oncogene
Reprogramming of miRNA networks in cancer and leukemia. 20439436 Genome Res.
Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. 20051373 Cancer Prev Res (Phila)
Interplay between microRNAs and the epigenetic machinery: an intricate network. 20493980 Biochim. Biophys. Acta
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. 20388878 J. Natl. Cancer Inst.
Modulation of mismatch repair and genomic stability by miR-155. 20351277 Proc. Natl. Acad. Sci. U.S.A.
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. 21300873 Proc. Natl. Acad. Sci. U.S.A.
Oncogenic role of miR-483-3p at the IGF2/483 locus. 20388800 Cancer Res.
Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. 19926640 Carcinogenesis
MicroRNAs as regulators of death receptors signaling. 19644509 Cell Death Differ.
miR-EdiTar: a database of predicted A-to-I edited miRNA target sites. 23044546 Bioinformatics
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. 22210864 Nucleic Acids Res.
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. 22351564 EMBO Mol Med
CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. 20802525 Oncogene
microRNAs: Master regulators as potential therapeutics in cancer. 20809797 Annu. Rev. Pharmacol. Toxicol.
miRNAs in precancerous lesions of the gastrointestinal tract. 22219591 World J. Gastroenterol.
microRNA involvement in human cancer. 22491715 Carcinogenesis
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. 22986525 Oncogene
Causes and consequences of microRNA dysregulation. 22647357 Cancer J
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). 21078976 Proc. Natl. Acad. Sci. U.S.A.
Mutated beta-catenin evades a microRNA-dependent regulatory loop. 21383185 Proc. Natl. Acad. Sci. U.S.A.
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. 21383199 Proc. Natl. Acad. Sci. U.S.A.
MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. 23012423 Proc. Natl. Acad. Sci. U.S.A.
miRNAs in the spotlight: Understanding cancer gene dependency. 21818092 Nat. Med.
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. 22157681 Nat. Med.
Role of microRNAs in lymphoid biology and disease. 21519241 Curr. Opin. Hematol.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

1082 Biomedical Research Tower, 460 W 12th Avenue
The Ohio State University Medical Center

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 06/30/2017

The next EDRN Steering Committee Meeting is from September 12-14, 2017, in Seattle WA. Please click here to register and find out more information about the meeting.

Announcement



EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.